Prior nasal delivery of antagomiR-122 prevents radiation-induced brain injury

Haihong Zhou,Furong Sun,Mingqian Ou,Yu Zhang,Meijun Lin,Liqin Song,Yangsheng Yu,Haojie Liao,Weihao Fan,Huaijie Xing,Minhua Li,Kui Zhao,Xiaolian Wu,Yuanhong Sun,Chunmei Liang,Yujie Cai,Lili Cui
DOI: https://doi.org/10.1016/j.ymthe.2021.06.019
IF: 12.91
2021-12-01
Molecular Therapy
Abstract:<p>Radiation-induced brain injury is a major adverse event in head and neck tumour treatment, influencing the quality of life over 50% of patients who undergo radiation therapy and experience long-term survival. However, no effective treatments are available for these patients, and preventative drugs and effective drug delivery methods must be developed. Based on our results, miR-122-5p was upregulated in the mouse radiation-induced brain injury (RBI) model and patients with nasopharyngeal carcinoma (NPC) who received radiation therapy. Intranasal administration of a single antagomiR-122-5p dose before irradiation effectively alleviated radiation-induced cognitive impairment, neuronal injury, and neuroinflammation in the mouse RBI model. We further indicated that miR-122-5p inhibition in microglia reduced the levels of proinflammatory cytokines and enhanced phagocytic function to protect against radiation-induced neuronal injury in cell models. Further, we profiled transcriptome data and verified that Tensin 1 (<em>TNS1</em>) may be the target of miR-122-5p in RBI. In summary, our results reveal a distinct role for miR-122-5p in regulating neuroinflammation in RBI, indicating that a non-invasive strategy for intranasal miR-122-5p administration may be an attractive therapeutic target in RBI, providing new insights for clinical trials. The further systematic safety assessment, further optimization of drug administration and clarity of mechanism will accelerate the clinical practice.</p>
genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology
What problem does this paper attempt to address?